Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis

The abundance of the BCR/ABL protein critically contributes to CML pathogenesis and drug resistance. However, understanding of molecular mechanisms underlying BCR/ABL gene regulation remains incomplete. While BCR/ABL kinase inhibitors have shown unprecedented efficacy in the clinic, most patients re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiaojuan, Pang, Jiuxia, Shen, Na, Yan, Fei, Wu, Lai-Chu, Al-Kali, Aref, Litzow, Mark R., Peng, Yong, Lee, Robert J., Liu, Shujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095007/
https://www.ncbi.nlm.nih.gov/pubmed/27144331
http://dx.doi.org/10.18632/oncotarget.8871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095007/
https://www.ncbi.nlm.nih.gov/pubmed/27144331
http://dx.doi.org/10.18632/oncotarget.8871

Ejemplares similares